Cipla share price falls over 2% after weak Q3FY26 results; profit drops 57% YoY, brokerages cut targets citing US headwinds.

Jan 23 (Reuters) - Cipla, India's third-largest drugmaker by revenue, reported a 57% quarterly profit decline on Friday as ...

Jan 23 (Reuters) - Cipla, India's third-largest drugmaker by revenue, reported a steeper-than-expected 57% fall in quarterly ...

Prior to joining Cipla, Kakatkar has held senior leadership positions with several reputed global organisations, including ...

Pharmaceutical major Cipla’s net profit dropped 57 per cent year-on-year (Y-o-Y) to Rs 675 crore in the third quarter of the ...

Stay updated with the Cipla Stock Liveblog, your one-stop destination for real-time information and analysis of a leading stock. Explore the latest updates on Cipla stock, including: Last traded price ...

Cipla Limited partners with ImmunoACT to launch talicabtagene autoleucel CAR-T therapy for blood cancers in South Africa, ...

Several brokerages downgraded Cipla following a weaker-than-expected December quarter performance, citing softness in US ...

Cipla shares traded lower after the drugmaker reported a sharp year-on-year decline in December-quarter profit, prompting ...

Our current focus remains on tirzepatide in terms of being the best‑in‑class molecule,” said Achin Gupta, Cipla’s Managing ...

Jefferies downgraded Syngene to 'underperform' and slashed price target to Rs 480 from Rs 660; JPMorgan downgraded Cipla to ...

Indian pharmaceutical major Cipla on Friday reported a sharp decline in its consolidated net profit for the third quarter of ...